Evidence map›Paper›PMID 31994346›Full record

ArticleThoracic cancer2020

MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC).

Jipei Liao, Jun Shen, Qixin Leng, Meng Qin, Min Zhan, Feng Jiang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review: Detection of Cancer Biomarkers from a Clinical Perspective.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Phosphorylation of AGO2 by TBK1 Promotes the Formation of Oncogenic miRISC in NSCLC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jipei LiaoDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jun ShenDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Qixin LengDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Meng QinDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Min ZhanDepartment of Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Feng JiangDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-8510-3049
University of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe development of biomarkers for the early detection of non-small cell lung cancer (NSCLC) is clinically important. We have developed miRNA biomarkers in sputum and plasma, respectively, for NSCLC. Herein, we evaluate whether integrated analysis of the miRNAs across the different types of specimens could improve the early detection of NSCLC.

methodsUsing reverse transcription PCR, we determined expressions of two miRNAs (miRs-31-5p and 210-3p) in sputum and three miRNAs (miRs-21-5p, 210-3p, and 486-5p) in plasma of a training cohort of 76 NSCLC patients and 72 cancer-free smokers. The results were validated in a testing cohort of 56 NSCLC patients and 55 cancer-free smokers.

resultsThe panels of two sputum miRNAs and three plasma miRNAs had 65.8-75.0% sensitivities and 83.3-87.5% specificities for diagnosis of NSCLC in the training cohort. The individual sputum or plasma miRNA panel had a higher sensitivity for squamous cell carcinoma or adenocarcinoma of the lung, respectively. From the miRNAs, we optimized an integrated panel of biomarkers consisting of two sputum miRNAs (miRs-31-5p and 210-3p) and one plasma miRNA (miR-21-5p) that had higher sensitivity (85.5%) and specificity (91.7%) for diagnosis of NSCLC compared with the individual panels alone. Furthermore, the performance of the integrated panel of biomarkers was independent of histology and stage of NSCLC, and patients' age, sex, and ethnicity. The performance of the integrated panel of biomarkers was confirmed in the testing cohort.

conclusionsIntegrating biomarkers across different body fluids would synergistically improve the early detection of NSCLC. KEY POINTS: Lung cancer is a heterogeneous disease and develops from complex aberrations. Integrating sputum and plasma miRNAs has higher accuracy than when they are used alone.

Indexed as

Adenocarcinoma of LungAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCase-Control StudiesCohort StudiesEarly Detection of CancerFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLung NeoplasmsMaleBiomarkers, TumorMicroRNAsBiomarkersdiagnosislung cancermicroRNAplasmasputum

Identifiers

PMID31994346
PMCPMC7049510
OpenAlexW3003243240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.